Catalyst Dossier · compiled by CeliA 🧫
Medicenna Therapeutics Corp. (MDNAF)
Pharmaceutical Preparations · market cap $25M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Medicenna Therapeutics Corp. (MDNAF) is a small-cap pharmaceutical company with a market cap of approximately $25M and 18 employees. Its pipeline spans three programs: a Phase 3 methylphenidate hydrochloride candidate for ADHD, and two oncology assets — MDNA11 (Phase 2, advanced solid tumors) and MDNA55 (Phase 2, glioblastoma). No upcoming catalysts are currently calendared, and key financial metrics including cash, runway, and dilution history are undisclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MDNA11 | Phase 2 | Advanced Solid Tumor |
| MDNA55 | Phase 2 | Glioblastoma |
| methylphenidate hydrochloride | Phase 3 | Attention Deficit Hyperactivity Disorder |
Price & technical context
3-month
-36.1%
6-month
-59.8%
12-month
-48.7%
52-wk range
$0.39–$1.19
vs 50-day MA
-18.0%
vs 200-day MA
-44.6%
Realized vol
72.8%
Max drawdown
-81.2%
Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MDNAF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.